Annals of Hematology最新文献

{"title":"Outcomes of primary CNS lymphoma treated with combined immunochemotherapy with whole-brain radiotherapy.","authors":"Ya Hwee Tan, Ryan Mao Heng Lim, Jing Yuan Tan, Boon Yee Lim, Nur Ayuni Binte, Muhammad Taib, Choon Kiat Ong, Chee Leong Cheng, Kheng Wei Yeoh, Soon Thye Lim, Jason Yongsheng Chan","doi":"10.1007/s00277-025-06561-1","DOIUrl":"https://doi.org/10.1007/s00277-025-06561-1","url":null,"abstract":"<p><strong>Purpose: </strong>Given that most PCNSL cases are diagnosed at a late age, they may be unsuitable for consolidation therapy with autologous stem cell transplantation (HDC-ASCT). We thus examine the outcomes of PCNSL in a multiethnic Asian population treated with HD-MTX-based chemotherapy and consolidation WBRT, so as to benchmark current treatment outcomes.</p><p><strong>Methods: </strong>We conducted a retrospective study involving patients (n = 129) diagnosed with PCNSL at the National Cancer Centre Singapore from 2000 to 2019. The median follow-up duration was 47.0 months. Survival analyses were performed using the Kaplan-Meier method and Cox proportional models.</p><p><strong>Results: </strong>The cohort consisted of 76 male and 53 female patients with a median age of 60 years. 85 patients received HD-MTX-based induction therapy as per DeAngelis, while 44 were treated with the Shah protocol. In univariate analyses, male sex, ECOG scores ≥ 1, non-germinal center subtype, use of DeAngelis protocol, and methotrexate dose < 3 g/m² were significantly correlated with worse PFS and OS. In a multivariate model, the Shah protocol conferred significantly improved outcomes as compared with the DeAngelis protocol for PFS (HR 0.43, 95% CI 0.25-0.73, p = 0.0019) and OS (HR 0.31, 95% CI 0.16-0.59, p = 0.0004). Using gene expression profiling, poor risk PCNSL patients had a higher trend of CD8 T-cells, macrophages and Th-1 cells, upregulation of TIGIT and HAVCR2, and downregulation in WNT11 and CD44.</p><p><strong>Conclusion: </strong>Our study demonstrates that contemporary HD-MTX-based chemoimmunotherapy induction regimens achieve good disease responses in PCNSL. We also highlight significant prognostic factors and a potential role for immunotherapy in PCNSL.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients.","authors":"Bingxin Qian, Guiqin Huang, Xiaoya Cai, Ying Liu, Dengju Li, Jin Yin","doi":"10.1007/s00277-025-06551-3","DOIUrl":"https://doi.org/10.1007/s00277-025-06551-3","url":null,"abstract":"<p><p>High-dose cytarabine has been the frontline therapy for the consolidation treatment of acute myeloid leukemia for many years. Current guidelines suggest that the combination of anthracyclines with high-dose cytarabine can be considered an option for consolidation therapy in certain patients. However, the research in this area is limited. This study aimed to investigate whether consolidation therapy with high doses of cytarabine in combination with idarubicin could result in better long-term survival. A total of 102 patients who achieved complete response and underwent consolidated treatment more than twice were included in the analysis. In this study, 49 patients received high-dose cytarabine alone for consolidation chemotherapy (HDAC group), and 53 patients received idarubicin in combination with high-dose cytarabine for consolidation chemotherapy (IHDAC group). The use of idarubicin in combination with high-dose cytarabine in consolidation therapy did not lead to a better long-term prognosis in patients than high-dose cytarabine alone. Patients treated with idarubicin required a significantly longer time to recover from agranulocytosis during hospitalization and had a higher incidence of infections.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphoma and Long-Term cardiovascular disease risk: A comprehensive analysis from the UK biobank.","authors":"Chenliang Ge, Yan He, Feng Huang, Zhiyu Zeng","doi":"10.1007/s00277-025-06544-2","DOIUrl":"https://doi.org/10.1007/s00277-025-06544-2","url":null,"abstract":"<p><p>Lymphoma survivors may face an increased risk of cardiovascular diseases (CVDs), but large-scale studies comprehensively assessing this risk are limited. This study aims to investigate the association between lymphoma and incident CVDs, and to explore differences across lymphoma subtypes and potential effect modifiers. This retrospective cohort study used UK Biobank data. 3,244 lymphoma patients were matched 1:5 to 16,208 non-cancer controls based on demographics, lifestyle, and health factors. Incident CVDs were ascertained from electronic health records. Multivariable Cox proportional hazards regression was used to assess the association between lymphoma and each cardiovascular outcome, adjusting for key demographic, lifestyle, and clinical factors. After multivariable adjustment, lymphoma was significantly associated with increased risks of myocarditis/pericarditis (HR: 3.24, 95% CI: 2.26-4.63), heart failure/cardiomyopathy (HR: 2.65, 95% CI: 2.26-3.11), atrial fibrillation/flutter (HR: 1.80, 95% CI: 1.58-2.04), valve diseases (HR: 1.80, 95% CI: 1.47-2.19), conduction system disease (HR: 1.65, 95% CI: 1.37-1.98), supraventricular arrhythmias (HR: 1.52, 95% CI: 1.07-2.17), peripheral arterial disease (HR: 1.47, 95% CI: 1.18-1.84), and ischemic heart disease (HR: 1.18, 95% CI: 1.04-1.34). Risk varied significantly across lymphoma subtypes, with Diffuse Large B-cell Lymphoma (DLBCL) and peripheral/cutaneous T-cell lymphomas exhibiting particularly elevated risks for several outcomes. Subgroup analyses indicated that age, sex, body mass index (BMI), and hypertension status significantly modified some associations. Lymphoma is associated with a significantly increased risk of multiple CVDs. Findings highlight the need for cardiovascular risk assessment and tailored management in lymphoma survivors, considering subtype and individual risk factors.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The global, regional, and national burden of Non-Hodgkin lymphoma in 204 countries and territories and 811 subnational locations, 1990-2021: an update from the Global Burden of Disease Study 2021.","authors":"Tong Li, Xiaojie Liang, Bingyu Lin, Baiwei Luo, Dan Liu, Weixiang Lu, Shengyu Tian, Jia Guo, Xinyu Zhou, Zhihao Jin, Yuquan Huang, Shipeng Guo","doi":"10.1007/s00277-025-06559-9","DOIUrl":"https://doi.org/10.1007/s00277-025-06559-9","url":null,"abstract":"<p><p>Non-Hodgkin lymphoma (NHL) constitutes a significant portion of the global cancer burden and associated mortality. However, a comprehensive understanding of NHL's scale and trends remains limited, underscoring the need for evidence-based epidemiological research to inform healthcare decisions and planning effectively. Incidence, mortality, and disability-adjusted life-years (DALYs) estimates, along with 95% uncertainty intervals (UIs), were derived from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. This study delineates NHL epidemiology by sex and age categories globally, regionally, and nationally. It examines NHL burden trends from 1990 to 2021 across various dimensions, analyzes burden breakdowns by population size, age structure, and epidemiologic changes, assesses cross-country inequalities using WHO-endorsed health equity methodologies, and projects NHL burden changes over the next 30 years. Notably, it explores how social development levels influence NHL epidemiological patterns and utilizes frontier analysis to evaluate health potential across different countries and regions. In 2021, 604,554 individuals (95% UI: 558,229-648,746) were diagnosed with NHL, and NHL-related deaths totaled 267,061 (95% UI: 246,095-288,696). From 1990 to 2021, the total number of newly diagnosed cases rose from 255,668 (95% UI: 242,749-272,801) to 604,554 (95% UI: 558,229-648,746); deaths grew from 146,657 (95% UI: 136,931-160,542) to 267,061 (95% UI: 246,095-288,696); and DALYs surged from 5,199,945 (95% UI: 4,797,150-5,770,129) to 7,766,063 (95% UI: 7,130,942-8,486,078). At the regional level, Andean Latin America had the highest ASIR, with 20.2 cases per 100,000 people (95% UI 16.13-25.26). At the national level, Peru recorded the highest age-standardized incidence rate (24.00 [95% UI 17.61-31.1] per 100,000). High-SDI regions exhibited sharp declines in age-standardized DALYs rates. Cross-country inequality increased from 22.68 DALYs per 100,000 in 1990, to 66.26 in 2021. Population growth appeared to have the most significant influence on incidence rates. Frontier analysis reveals that middle and upper-middle SDI countries have greater potential for health improvements. It is projected that the age-standardized rates (ASR) for mortality and DALYs will continue to decline up to 2051. Over the past three decades, NHL burden has intensified, necessitating increased health resources to address challenges associated with aging populations. Currently, high-SDI countries experience the highest NHL incidence and mortality rates, while developing nations with moderate to low-middle SDI levels must enhance efforts to manage the rising NHL burden effectively.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of baseline body composition parameters from ¹⁸F-FDG PET/CT in angioimmunoblastic T-cell lymphoma patients.","authors":"Huanyu Gong, Jingjie Shang, Jianyong Li, Chongyang Ding, Hao Xu, Lijun Tang, Yong Cheng","doi":"10.1007/s00277-025-06562-0","DOIUrl":"https://doi.org/10.1007/s00277-025-06562-0","url":null,"abstract":"<p><p>This retrospective study investigated preliminarily the prognostic value of body composition parameters derived from baseline ¹⁸F-FDG PET/CT in angioimmunoblastic T-cell lymphoma (AITL) patients. We included 94 treatment-naïve AITL patients diagnosed by histopathology. Based on the axial CT images of the third lumbar vertebra, the areas of skeletal muscle (SM), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were semi-automatically delineated and standardized to finally obtain SM index (SMI), VAT index (VATI), and SAT index (SATI). Body composition density characterized by CT attenuation was obtained, including SM density (SMD), VAT density (VATD), and SAT density (SATD). Besides, the maximum standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG) were also calculated. Endpoints included progression-free survival (PFS) and overall survival (OS). Survival curves and Cox regression analysis were performed‌‌.Of 94 AITL patients(mean age:63.4 ± 9.7 years,67% men), 65 progressed and 55 died[median follow-up: 27.5 (10.5-45.7) months].High baseline C-reactive protein level [hazard ratio (HR) = 2.47, 95%CI: 1.37-4.45, p = 0.003), low SMD (HR = 2.18, 95%CI:1.29-3.69, p = 0.003), high SATD (HR = 1.92, 95%CI: 1.05-3.54, p = 0.035), and low VATI (HR = 1.95, 95%CI: 1.12-3.38, p = 0.018) were independent risk factors for poor PFS. AITL score>2(HR = 2.90, 95%CI: 1.59-5.29, p < 0.001), sarcopenia(HR = 1.78, 95%CI: 1.01-3.12,p = 0.045), low VATI(HR = 2.24,95%CI: 1.27-3.95,p = 0.005), and high TMTV(HR = 2.46, 95%CI: 1.37-4.40, p = 0.003) may serve as independent risk factors for poor OS. In conclusion, in addition to conventional TMTV, body composition parameters derived from baseline ¹⁸F-FDG PET/CT may offer preliminary prognostic value for AITL patients.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.","authors":"Alessandra D'Addio, Michela Rondoni, Marzia Salvucci, Giovanni Marconi, Massimiliano Bonifacio, Ilaria Tanasi, Omar Perbellini, Giuseppe Carli, Patrizia Tosi, Simona Tomassetti, Giovanni Poletti, Evita Massari, Marco Rosetti, Elisabetta Fabbri, Chiara Zingaretti, Alessandro Lucchesi, Maria Teresa Bochicchio, Giorgia Simonetti, Mauro Krampera, Francesco Lanza","doi":"10.1007/s00277-025-06556-y","DOIUrl":"https://doi.org/10.1007/s00277-025-06556-y","url":null,"abstract":"<p><p>The prevalence of paroxysmal nocturnal hemoglobinuria (PNH) clones is little investigated in myeloproliferative neoplasms (MPN) patients. The aim of this multicenter study was to evaluate the prevalence of PNH clones (glycosyl-phosphatidyl-inositol lacking) in 119 Ph- negative MPN patients having anemia, LDH elevation, asthenia and history of thrombosis. All the participating centers performed the standardized diagnostic test by using a single lyophilized template for granulocytes, monocytes, and erythrocytes. Next generation sequencing (NGS) was performed in 2 PNH-positive MPN cases and 13 PNH-negative MPN. The prevalence of PNH positive clones was 3.23% (n. 3 patients). All three patients had splenomegaly; none of them had thrombosis. One patient affected by CALR mutated essential thrombocytopenia, had a small clone (0.52%), clinically irrelevant; one patient affected by JAK2^V617F primary myelofibrosis (PMF) showed a PNH clone of 89.8%, severe anemia and hemoglobinuria and started eculizumab therapy; the third patient affected by CALR mutated PMF showed a PNH clone of 92.6% but without severe anemia and breakthrough hemolysis and eculizumab therapy was not undertaken. PIGA deletion was detected in PNH-positive cases along with mutations of myeloid-related genes. These data seem to suggest an association of CALR mutation and JAK2^V617F mutation with PNH positive clones suggesting that the worsening of malignant process may be associated with the acquisition of multiple genetic mutations.Clinical Trial Registration: NCT06159816.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144939982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-plasma cell therapy in patients with monoclonal gammopathy-associated refractory pure red cell aplasia: A report of three cases and literature review.","authors":"Li Huang, Meng Li, Ting Niu, Hong Chang","doi":"10.1007/s00277-025-06565-x","DOIUrl":"https://doi.org/10.1007/s00277-025-06565-x","url":null,"abstract":"<p><p>Acquired pure red cell aplasia (aPRCA) is a clinical syndrome that may be secondary to a diverse array of diseases. It is rarely secondary to monoclonal gammopathy of undetermined significance (MGUS). Currently, there is no consensus on when to initiate anti-plasma cell therapy. This study reports three cases of patients with MGUS-associated aPRCA who responded to anti-plasma cell therapy after failing conventional immunosuppressive treatment. Patient 1 achieved complete remission after treatment with the BD (bortezomib and dexamethasone) and BRD (bortezomib, lenalidomide, and dexamethasone) regimens. She subsequently received lenalidomide as maintenance treatment. She has remained in treatment-free survival (TFS) for 22 months to date. Patient 2 achieved complete remission after treatment with the BRD regimen and was maintained with lenalidomide. She has maintained TFS for 16 months so far. Patient 3 was treated with the BD regimen and became transfusion-independent, but relapsed after treatment discontinuation due to COVID-19 infection.This study suggests that anti-plasma cell therapy may be an effective strategy for aPRCA patients unresponsive to conventional immunosuppressive therapy and exhibiting monoclonal protein (M-protein). However, further studies are needed to explore the optimal timing and duration of such therapy.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial local treatment strategies on survival outcomes of early-stage breast mucosa-associated lymphoid tissue lymphoma.","authors":"Hong-Yu Chen, San-Gang Wu, Zhen-Yu He","doi":"10.1007/s00277-025-06520-w","DOIUrl":"https://doi.org/10.1007/s00277-025-06520-w","url":null,"abstract":"<p><p>To compare survival outcomes among different initial treatment strategies for early-stage (stage I-II) breast mucosa-associated lymphoid tissue (MALT) lymphoma. Using data from the Surveillance, Epidemiology, and End Results program, we analyzed patients diagnosed with early-stage breast MALT lymphoma between 2000 and 2017. Statistical analyses included chi-square tests, Kaplan-Meier survival estimates, and multivariate Cox proportional-hazards models. Among 396 eligible patients, treatment strategies included surgery with or without postoperative radiotherapy (161 patients, 40.7%), radiotherapy alone (122 patients, 30.8%), and observation (113 patients, 28.5%). Temporal trends indicated increasing use of radiotherapy alone, while surgery alone and observation declined (P = 0.061). With a median follow-up of 94 months, the 8-year cancer-specific survival (CSS) and overall survival (OS) rates were 88.7% and 71.9%, respectively. Patients receiving local treatment (surgery and/or radiotherapy) alone demonstrated superior CSS (P = 0.002) and OS (P < 0.001) compared to observation. However, adding chemotherapy to local treatment was associated with worse CSS (P = 0.017) and OS (P = 0.003). Sensitivity analysis revealed no significant differences in CSS or OS among local treatment modalities (surgery alone, radiotherapy alone, or combined surgery and radiotherapy). Radiotherapy alone can achieve the optimal disease control for early-stage breast MALT lymphoma. The role of surgery is rather limited and is mainly considered when there is a diagnostic dilemma.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of fecal microbiome in Chinese patients with non-severe aplastic anemia","authors":"Xiaolan Zhang,&nbsp;Jingjing Xie,&nbsp;Heng Wang,&nbsp;Jun Li","doi":"10.1007/s00277-025-06459-y","DOIUrl":"10.1007/s00277-025-06459-y","url":null,"abstract":"<div><p>By analyzing the fecal microbiome data of patients with non-severe aplastic anemia (NSAA), this study aims to explore the potential role of dysbiosis in the immune-mediated pathogenesis of NSAA. This study included 21 newly diagnosed NSAA patients from the Affiliated Hospital of Nanjing University of Chinese Medicine between July 2018 and June 2021, along with 24 healthy controls who underwent routine health checkups. Fecal samples were collected for DNA extraction. At the species level of phylum, class, order, family, genus and species, the intestinal microbial community of NSAA patients was significantly different from that of healthy controls. Alpha diversity analysis showed that the Chao and Observed species indices were significantly lower in the NSAA group compared to the control group ( <i>P</i> &lt; 0.05 ), indicating that the gut microbiota diversity in NSAA patients was lower than that in normal individuals. Further multivariate statistical analysis revealed that the relative abundance of the following gut microbiota was higher in the NSAA group: Actinobacteriota, Coriobacteriia, Bifidobacteriales, Coriobacteriales, Pasteurellales, Prevotellaceae, Muribaculaceae, Bifidobacteriaceae, Coriobacteriaceae, Pasteurellaceae, <i>Prevotella</i> spp., <i>Muribaculum</i> spp., <i>Barnesiella</i> spp., <i>Bifidobacterium</i> spp., <i>Mitsuokella</i> spp., <i>Collinsella</i> spp., <i>Alloprevotella</i> spp. Meanwhile, the abundance of <i>Lachnospirales</i> spp. in the gut microbiota of NSAA patients was found to be lower than that of healthy controls. Correlation and model prediction analyses of the dominant microbial species in both the NSAA and control groups revealed a strong competitive relationship between <i>Bacteroides</i> spp. and <i>Prevotella</i> spp. NSAA patients exhibit a decrease in the abundance of <i>Lachnospirales</i> spp. and an increase in the abundance of <i>Prevotella</i> spp., which may be closely related to immune dysfunction mediated by NSAA Treg/Th17 imbalance, which, in turn, may contribute to the development of hematopoietic failure.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 8","pages":"4013 - 4027"},"PeriodicalIF":2.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-025-06459-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirolimus modulates the erythroid differentiation of K562 cells by upregulating SHP1","authors":"Yuan Yang,&nbsp;Zengwei Tang,&nbsp;Qinglin Hu,&nbsp;Chen Yang,&nbsp;Miao Chen,&nbsp;Hongmei Jing,&nbsp;Bing Han","doi":"10.1007/s00277-025-06518-4","DOIUrl":"10.1007/s00277-025-06518-4","url":null,"abstract":"<div><p>Sirolimus is an effective treatment for acquired pure red cell aplasia (aPRCA), but the detail mechanism of sirolimus on red cell differentiation is incompletely understood. The aim of the study was to investigate whether sirolimus can induce the erythroid differentiation of K562 cells and investigate the potential regulation mechanism. Benzidine staining and flow cytometry were performed to determine the benzidine-/CD71-positive K562 cells with or without sirolimus treatment. The expression level of α-/ γ-globin in each group was determined by real-time qPCR, respectively. siRNA-targeted assays were performed to investigate the role of protein tyrosine phosphatase 1 (SHP1) in sirolimus-induced erythroid differentiation of K562 cells. The proportion of benzidine-staining/CD71-positive cells, and α- / γ-globin mRNA expression were increased in K562 cells treated with sirolimus. Sirolimus markedly inhibited mTOR and p-mTOR expression while upregulated SHP1 expression in K562 cells. Knockdown of SHP1 decrease α-/γ-globin mRNA level, CD71 protein expression levels and the proportion of benzidine-positive cells in the K562 cells. Additionally, knockdown of SHP1 can reverse the sirolimus-induced erythroid differentiation of K562 cells. Sirolimus treatment can promote the erythroid differentiation of K562 cells via upregulating of SHP1.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"104 8","pages":"4101 - 4109"},"PeriodicalIF":2.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-025-06518-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144871097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}